Abstract
Leukemia cutis describes cutaneous lesions produced by infiltrates of leukemic cells. It usually manifests contemporaneously with the initial diagnosis of systemic leukemia, but may also precede or follow systemic leukemia. Most cases are associated with acute myeloid leukemia. Adult B-cell lymphoblastic leukemia cutis is very rare. We report a 59-year-old woman with a history of B-cell acute lymphoblastic leukemia who relapsed with aleukemic lymphoblastic leukemia cutis. Lymphoglandular bodies were conspicuous on biopsy and may serve as a morphologic clue to lymphocytic differentiation while molecular and immunophenotypic studies are pending. The patient was successfully treated with local radiation therapy and oral ponatinib.
MeSH terms
-
Allografts
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Combined Modality Therapy
-
Cord Blood Stem Cell Transplantation
-
Dasatinib / administration & dosage
-
Dermis / ultrastructure*
-
Female
-
Fusion Proteins, bcr-abl / antagonists & inhibitors
-
Fusion Proteins, bcr-abl / genetics
-
Humans
-
Imidazoles / therapeutic use
-
Immunophenotyping
-
Leukemic Infiltration / diagnosis
-
Leukemic Infiltration / drug therapy
-
Leukemic Infiltration / pathology*
-
Leukemic Infiltration / radiotherapy
-
Middle Aged
-
Neoplasm Proteins / antagonists & inhibitors
-
Neoplasm Proteins / genetics
-
Philadelphia Chromosome
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology*
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
-
Protein Kinase Inhibitors / therapeutic use
-
Pyridazines / therapeutic use
-
Recurrence
-
Remission Induction
-
Scalp / pathology*
Substances
-
Antineoplastic Agents
-
Imidazoles
-
Neoplasm Proteins
-
Protein Kinase Inhibitors
-
Pyridazines
-
ponatinib
-
Fusion Proteins, bcr-abl
-
Dasatinib